N/A
Completed N=309
Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit
Source: ClinicalTrials.gov NCT06334042 ↗Enrolled (actual)
309
Serious AEs
—
Results posted
Apr 2025
Primary outcomePrimary: Serum Chromium Level — 8.93; 9.74; 9.68; 11.01 µg/L
Summary
The goal of this observational study is to determine the effects of chromium serum levels on glucose metabolism, lipid metabolism, morbidity and mortality rates in critically ill intensive care patients. The investigators' goal is to provide a different perspective on solving the common problems of hyperglycemia and dyslipidemia encountered in intensive care patients, aiming to reduce morbidity and mortality rates.
Participants will give a single blood sample (into trace element serum sample tube) on the day of admission to the intensive care unit, along with routine blood tests, and samples will be taken once a week during their stay in the intensive care unit.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Chromium Level |
8.93; 9.74; 9.68; 11.01 | — |
| SECONDARY HbA1c |
5.99 | — |
| SECONDARY Blood Glucose |
128.68; 122.25; 122.29; 116.46 | — |
| SECONDARY Lipid Profile |
118.28; 135.06; 124.29; 145.23; 38.93; 29.7 | — |
| SECONDARY Glycemic Variability - Coefficient of Variation (CV) |
22.01 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old
- Admitted to Anesthesiology Intensive Care Unit
Exclusion Criteria
- Patient Refusal
- Taking Chromium Supplement
Data sourced from ClinicalTrials.gov (NCT06334042). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.